RxDoctor Payments Data

James Wallace, MD

Internal Medicine · Dillon, SCNPI 1265695126

Payments from drug & device makers

$10,971in general payments, 2019–2025

Across 694 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$740
  • Pfizer$695
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$670
  • GSK$570
  • Amgen$535
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$10,971100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)88$1,384
Novartis48$740
Pfizer49$695
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC62$670
GSK32$570
Amgen(2 entities)36$535
Lilly USA, LLC31$493
Abbott25$448
Ironwood Pharmaceuticals, Inc27$435
Merck29$430
Boehringer Ingelheim25$422
Bayer27$411
Forte Bio-pharma LLC12$292
Johnson & Johnson21$292
Amarin Pharma, Inc.16$281
Sunovion Pharmaceuticals Inc.18$265
AstraZeneca14$195
Dexcom, Inc.6$189
Boston Scientific3$180
Corcept Therapeutics8$164
Sumitomo Pharma America, Inc.8$155
Astellas Pharma US Inc8$119
Mylan Specialty L.p.8$116
Takeda Pharmaceuticals U.S.A., Inc.8$113
Novo Nordisk8$109
Exact Sciences6$104
Otsuka America Pharmaceutical, Inc.4$96
Daiichi Sankyo Inc.5$85
Esperion Therapeutics, Inc.5$83
E.r. Squibb & Sons, L.L.C.6$82
Vifor Pharma, Inc.4$60
Axsome Therapeutics, Inc.3$55
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$54
Sanofi-aventis U.S. LLC3$50
Seqirus USA Inc2$49
Biohaven Pharmaceuticals, Inc.3$47
Biohaven Pharmaceutical Holding Company Ltd.2$46
Shield Therapeutics Inc2$35
Almatica Pharma LLC2$33
Upsher-smith Laboratories LLC2$32
Idorsia Pharmaceuticals US Inc2$31
Nestle Healthcare Nutrition Inc.2$29
Genentech USA, Inc.2$28
Avion Pharmaceuticals2$27
Xeris Pharmaceuticals, Inc.2$26
Vapotherm Inc2$23
Ardelyx, Inc.1$22
Ascensia Diabetes Care US Inc.1$21
Sanofi Pasteur Inc.1$21
Phathom Pharmaceuticals, Inc.2$20
Aimmune Therapeutics, Inc.1$17
The Binding Site Inc.1$14
Eisai Inc.1$13
Dynavax Technologies Corporation1$13
Gilead1$12
Ultragenyx Pharmaceutical Inc.1$12
Teva Pharmaceuticals USA, Inc.1$11
Strongbridge US Inc.1$11
Cvrx, Inc.1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,971 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$154,959
Medicare patients
328
Services billed
2,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin135$135,511
EliquisApixaban115$97,310
TrulicityDulaglutide66$76,202
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$64,868
OzempicSemaglutide59$59,113
EntrestoSacubitril/Valsartan58$57,819
MounjaroTirzepatide43$53,596
FarxigaDapagliflozin Propanediol63$52,865
XareltoRivaroxaban25$30,808
LinzessLinaclotide31$25,294
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$23,900
MyrbetriqMirabegron27$18,789
RybelsusSemaglutide14$17,817
KerendiaFinerenone13$17,661
QuliptaAtogepant12$12,593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$422$141,621147 claims
Lilly USA, LLCTrulicity, Mounjaro$493$129,799109 claims
PfizerEliquis$695$97,310115 claims
Novo NordiskOzempic, Rybelsus$109$76,93073 claims
AstraZenecaFarxiga, Breztri Aerosphere$195$76,76589 claims
GSKTrelegy Ellipta$570$64,86895 claims
NovartisEntresto$740$57,81958 claims
AbbVieLinzess, Qulipta, Synthroid$1,384$39,40056 claims
Johnson & JohnsonXarelto$292$30,80825 claims
Astellas Pharma US IncMyrbetriq$119$18,78927 claims
BayerKerendia$411$17,66113 claims
MerckJanuvia, Janumet Xr$430$16,78626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Dillon

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →